Atreca, Inc. - (BCEL) News
Filter BCEL News Items
BCEL News Results
|Loading, please wait...|
BCEL News Highlights
- BCEL's 30 day story count now stands at 2.
- Over the past 16 days, the trend for BCEL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ATRC are the most mentioned tickers in articles about BCEL.
Latest BCEL News From Around the Web
Below are the latest news stories about Atreca Inc that investors may wish to consider to help them evaluate BCEL as an investment opportunity.
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will report fourth quarter 2021 financial results and members of the company’s management team will host a year-end conference call, which will include an update on progress in the ongoing ATRC-101
Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present data on broadly neutralizing SARS-CoV-2 antibodies discovered by the company at the upcoming Keystone Symposia Conference: Antibodies as Drugs, being held January 30 – February 2, 2022
Goldman Sachs Group Inc. cut its stake in shares of Atreca, Inc. (NASDAQ:BCEL) by 63.0% in the 2nd quarter, Holdings Channel reports. The fund owned 99,913 shares of the companys stock after selling 170,340 shares during the quarter. Goldman Sachs Group Inc.s holdings in Atreca were worth $851,000 as of its most recent filing with 
Atreca Inc. (NASDAQ:BCEL) has seen 1.87 million shares traded in the last trading session. The company, currently valued at $134.16M, closed the last trade at $3.59 per share which meant it lost -$0.36 on the day or -9.11% during that session. The BCEL stock price is -465.18% off its 52-week high price of $20.29 and Atreca Inc. (BCEL): What Is Good About Stock? Read More »
State Street Corp reduced its position in shares of Atreca, Inc. (NASDAQ:BCEL) by 56.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 491,632 shares of the companys stock after selling 634,868 shares during the quarter. State Street Corp owned 1.33% of Atreca worth 
Brokerages expect that Atreca, Inc. (NASDAQ:BCEL) will announce ($0.75) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Atrecas earnings, with estimates ranging from ($0.83) to ($0.69). Atreca reported earnings of ($0.63) per share in the same quarter last year, which would suggest a negative year-over-year 
The big shareholder groups in Atreca, Inc. ( NASDAQ:BCEL ) have power over the company. Large companies usually have...
Geode Capital Management LLC decreased its position in shares of Atreca, Inc. (NASDAQ:BCEL) by 1.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 449,553 shares of the companys stock after selling 5,659 shares during the quarter. Geode Capital Management LLCs holdings in Atreca 
Atreca Inc. (NASDAQ:BCEL) concluded the trading at $5.56 on Friday, November 12 with a fall of -0.54% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.59 and 5Y monthly beta was reading 0.03 with its price kept floating in the range At $5.56 Price, Atreca Inc. (BCEL) Is Sitting And Waiting Read More »